- Home
- PHAR vs PLRX Comparison
PHAR vs PLRX Comparison
Compare PHAR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- PLRX
- Stock Information
- Founded
- PHAR 1988
- PLRX 2015
- Country
- PHAR Netherlands
- PLRX United States
- Employees
- PHAR N/A
- PLRX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- PLRX Health Care
- Exchange
- PHAR Nasdaq
- PLRX Nasdaq
- Market Cap
- PHAR 618.3M
- PLRX 680.3M
- IPO Year
- PHAR N/A
- PLRX 2020
- Fundamental
- Price
- PHAR $8.20
- PLRX $11.37
- Analyst Decision
- PHAR Strong Buy
- PLRX Strong Buy
- Analyst Count
- PHAR 3
- PLRX 7
- Target Price
- PHAR $27.00
- PLRX $40.50
- AVG Volume (30 Days)
- PHAR 5.6K
- PLRX 485.5K
- Earning Date
- PHAR 03-13-2025
- PLRX 02-26-2025
- Dividend Yield
- PHAR N/A
- PLRX N/A
- EPS Growth
- PHAR N/A
- PLRX N/A
- EPS
- PHAR N/A
- PLRX N/A
- Revenue
- PHAR $285,745,000.00
- PLRX N/A
- Revenue This Year
- PHAR $20.08
- PLRX N/A
- Revenue Next Year
- PHAR $9.22
- PLRX N/A
- P/E Ratio
- PHAR N/A
- PLRX N/A
- Revenue Growth
- PHAR 30.64
- PLRX N/A
- 52 Week Low
- PHAR $6.65
- PLRX $10.22
- 52 Week High
- PHAR $13.20
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- PHAR 36.29
- PLRX 44.60
- Support Level
- PHAR $8.49
- PLRX $10.35
- Resistance Level
- PHAR $9.35
- PLRX $11.07
- Average True Range (ATR)
- PHAR 0.55
- PLRX 0.61
- MACD
- PHAR -0.17
- PLRX 0.06
- Stochastic Oscillator
- PHAR 12.14
- PLRX 43.50
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.